Subject index of volume 26

Actinomycin D 26
Activity 112
Acupuncture 239
Acute lymphoblastic leukemia 288
Acute myeloid leukemia 380
Acute nonlymphocytic leukemia 235
Adenocarcinoma 47
Adjuvant therapy S17
Adriamycin 333, S26, S39
Advanced breast cancer 75, 293, 457, S63, S71, S81, S87, S91, S93, S102
Advanced cancer 355
Advanced cervical cancer S33, S102
Advanced colonic cancer 352
Advanced malignancies 359
Alkylating agent 318
Alopecia 457
alpha-Difluoromethylornithine 223
Ambulatory pump 144
3-Aminobenzamide 37
Aminoglutethimide enzyme induction 241
Angiogenesis 461
Anthracycline 318
Anthracyclines 198, 227, 415, S81
Anticancer activities 263
Antiemetics 239
Antiestrogens 310
Antileukemic agents 173
Antineoplastic agents 245
Antitumor activity 37, 193
Antitumor agent 83
Aortic clamping 181
Autonomic nervous system 227

BCNU 155, 269, S78
Bis(2,6-dioxopiperazine) 193
Bleomycin 306, S12, S59
Bone marrow 155
Brain 263
Breast cancer 227, S78
Busulphan 19

Calcium channel blockers 310
Carboplatin 62, 101, 155, 232, 369, 464, S22, S48, S102
Carboplatin/ifosfamide S33
Carboxamide 168
Carcinoid tumors 62
Cardiac conduction 415
Cardiotoxicity 227, 403
CCNU 301
Cell cycle 42
Cell differentiation 26
Cell membranes 310
Cell proliferation 269
Cephalosporins 139
Cerebral metastases S78
Cerebrovascular permeability 263
Cervical cancer S1, S12, S59
Chemo-radiotherapy S74
Chemosensitivity 250
Chemosensitization in vivo 37
Chemotherapy 19, 65, 173, 205, 210, 373, 380, 457, S30, S43, S71
Childhood 288
Childhood solid tumors 343
Chlorambucil 301
Chlorethylnitrosourea 383
Cholinergic drugs 310
cis-Diamminedichloroplatinum(II) 278, 389, 423
Cisplatin 97, 159, 181, 188, 210, 235, 239, 306, 373, S12, S39, S59, S102
Cisplatin-based polychemotherapy 47
Cisplatin-containing regimens 52
Cisplatin-ifosfamide S36
Cisplatin resistance 42, S45
Clinical pharmacokinetics 419
Colorectal cancer 221
Colorectal infusion carcinoma 223
Combretastatin 79
Continuous-infusion 343, 352
Cortisone acetate 461
Cross-resistance 437
Cutaneous toxicity 449
Cyclodizone 19
Cyclophosphamide 155, S22
Cytosine arabinoside 135, 380
Cytotoxicity 1, 79, 135, 163, 345, 397, 403, 423, 429

Daunorubicin resistance 79
5-Day continuous infusion 389
DDP resistance 37
Delayed cytotoxicity 168
4-Demethoxydaunorubicin 297
4-Demethoxy-13-hydroxydaunorubicin 340
Dimethylformamide 26
Diphtheria toxin 409
Dipyridamole 135
DNA binding 257
DNA damage 340
DNA topoisomerase 257
Dose fractionation 144
Doxorubicin 9, 13, 163
Doxorubicin nanoparticles 122
Drug interaction 139
Drug penetration 198
Drug resistance 163

Early-stage cervical cancer S17
EDS 19
Endocrinology 241
Endometrial cancer S4
Epidoxorubicin 9, 453
Epirubicin S66, S69, S74
Epirubicin/verapamil S93
Ethacrynic acid 318
Ether lipids 437
Etoposide 52, 71, 147, 301, 306, 365, 380, S45
Etoposide-resistance 313
Evan's blue 461
Extracorporeal hemofiltration 210

Flavone acetic acid distribution 67
Flow cytometry 168
5-Fluorouracil 57, 159, 205, 352, 449, S66, S85, S102
Folinic acid 159
Fotemustine 467

Galactosamine toxicity 93
Ganglioside treatment 31
Gastrointestinal cancer 57
Genotoxicity 42
Glioma 383
Glutathione 397
Glycol alkyl ethers 173
(Glycolate-*O*,*O*')diammineplatinum(II) 393
Gynecological malignancies S39
Gynecological tumours S97
Gynecologic malignancies S55

Head and neck cancer 464
Heart 9
Hepatectomy 444
Hepatic toxicity 155
Hepatocytes 93
High-dose ifosfamide S91, S93
High-dose leucovorin 449
Hodgkin's disease 301
Hodgkin's lymphoma 306
HT-29 cells 323
Human breast cancer 245
Human colon carcinoma 323
Human tumour cells 42
Human tumour xenografts S7
Hydration 278
4-Hydroperoxycyclophosphamide 397
4-Hydroxyandrostenedione 75, 330
Hydroxyurea 345
Hyperthermia 127, 269
Hypoxic cell radiosensitizer 112

Idarubicin 297
Ifosfamide 71, 105, 373, 453, S1, S4, S7, S12, S22, S26, S30, S39, S43, S45, S48, S51, S59, S63, S66, S69, S71, S74, S78, S85, S97, S102, S102
Ifosfamide/cisplatin S102
Ifosfamide/etoposide S87
Ifosfamide/mesna S55
Ifosfamide/mitoxantrone S81
Ifosfamide stability 144
Imaging agents 42
Imidazotetrazines 429
Indicine-*N*-oxide 377
Interleukin-2 355, 409
Intrapleural chemotherapy 147
Isolated guinea-pig hearts 415

Kidney 278
KIH-802 112
KT6149 117

L-Cysteine derivative 88
Leucovorin 273
Leukemia 377
Leydig cells 19
Liver metastases 181
L1210 leukemia 215
Lung cancer 101
L5178Y leukemia 135

Maintenance chemotherapy 288
Malignant disease 437
Malignant tumors 67
MAP 65
mdr-1 313
Mechanism of action 117
6-Mercaptopurine 343

Mesna S1, S51, S63, S87, S91
Metabolism 105, 241, 429
Metastatic breast cancer S66, S74
Metastatic solid tumours S69
Methanesulphonates 19
Methotrexate 139, S85
Methotrexate S102
Mitochondrial DNA 97
Mitomycin C 333, 457
Mitomycin C derivative 117
Mitoxantrone 457
Mitozolomide 237
Monoblastic leukaemia 26
MST-16 193
Multicellular spheroids 151
Multidrug resistance 83, 151, 250
Murine neoplasia 215
Murine tumor models 193
Myeloblastic leukaemia 26
Myeloid leukemia cells 340

Nanoparticles 13
Na^+-pump 163
Neoadjuvant chemotherapy S36
Non-small-cell carcinoma 235
Non-small-cell lung cancer 52, 369, 373, 389, 393
Non-small-cell lung carcinoma 365
Novobiocin 257
N-β-Dimethylaminoethyl 9-carboxy-5-hydroxy-10-methoxybenz[a]phenazine-6-carboxamide 83
NSC 303861 88

Oestrogen 241
Oncolytic activity 88
Ototoxicity 232
Ovarian cancer 283, S22, S43, S48, S102
Ovarian cancer cells 333
Ovarian carcinoma 1, S30, S45
Ovarian tumors 37
Ovary cells 423

Paraganglioma 62
Pharmacokinetics 9, 112, 283, 330, 355, 365, 409, 444
Pharmacology 297, 359, 419
Phase II study 369, 373, 393
Phase I study 237
Plasma 9
Plasmid DNA 117
Polyamine inhibitors 65
Prednisolone 301
Protracted infusion 57
$Pt(Dye)_2$ complexes 127
PTT.119 215

Radio-chemotherapy S78
Rat transplant model 173
Recurrent ovarian cancer S51
Refractory breast cancer S69
Renal effects 467
Renal elimination 139
Renal toxicity 65
Resistant breast cancer S85
Reticulosarcoma 122
Ribonucleotide reductase inhibitors 323
Ribonucleotide reductase 345
Route of administration 205
4′-Deoxy-4′-iododoxorubicinol 403
4′-Epidoxorubicin 444
4′-*O*-Tetrahydropyranyldoxorubicin 293

Sarcosinamide 383
Secondary malignancy 235
Sensitivity testing 245
Small-cell lung cancer 71, 250, 313
Sodium cyanate 269
Soft-tissue sarcoma 453
Solid tumors 377
Spheroids 198
Squamous-cell carcinoma 464
Stage IV lung cancer 47
Statin 383
Stereoisomers 273
Subcellular distribution 188

Tallysomycin S 10b 221
Targeting 93, 188
Temozolomide 429
Testosterone 19
Thiazin 127
6-Thioguanine 168
6-Thioguanine nucleotide 288
thioTEPA 283
Thymidylate synthase 273
Tissue distribution 13, 122, 205
Topoisomerase 313
Topoisomerase II inhibitors 423
Toxicity 112, 359, 365
Trimethylcolchicinic acid 359
Tumor 9
Tumor necrosis factor 1
Two-route chemotherapy 181

Uroprotection S87
Uterine leiomyosarcoma S26
Uterine squamous-cell carcinoma S36

Verapamil hypersensitivity 151
Vinblastine 373, 464
Vincristine 31, 263
Vinzolidine 419

Xanthene 127